Nvidia Developer: Drug Discovery

OCTOBER 5, 2021

Recently published in the Proceedings of the National Academy of Sciences , the research develops a deep learning model that determines the best drug combinations for fighting the virus, despite having relatively limited data. These targets play a major role in drug therapy by creating a place for a drug to bind and inhibit disease growth.

Drugs 52

Drugs Virus Science Disease 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. aeruginosa hospital acquired pneumonia cases worldwide.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. ” COVID-19 was also a major focus of this year’s meeting. ” COVID-19 was also a major focus of this year’s meeting.

Research 52

Research Virus Therapies Trials 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

ACE2 is the receptor that the virus uses to gain entry. Solomon of Brigham and Women’s Hospital and Harvard Medical School, Boston, found that current evidence in humans is insufficient to support or refute claims that ACE inhibitors or ARBs may be helpful or harmful to individuals with COVID-19. The team, led by Scott D.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

The Pharma Data

NOVEMBER 22, 2020

The vaccine was effective at preventing COVID-19, with no hospitalizations or severe cases in people receiving it. They use mRNA that codes for the spike protein in the SARS-CoV-2 virus, which is embedded in a nanolipid particle—basically a minuscule fat molecule. Both the Pfizer-BioNTech and Moderna vaccines utilize mRNA technology.

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

AUGUST 30, 2021

Pulmonary infection with the SARS-CoV2 virus can progress to acute respiratory distress syndrome (ARDS), in which inflammation and neutrophil hyperactivation play a central role. There is currently a lack of therapies for ARDS associated with COVID-19.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

The Pharma Data

NOVEMBER 3, 2020

But, in some patients, COVID-19 appears to damage the nerve that regulates speech, causing their vocal cords to impede breathing even when they aren’t talking, said Dr. Jonathan Aviv, an ear, nose and throat specialist at Mount Sinai Hospital in New York City. “Think about when you’re chit-chatting.

Doctors 52

Doctors Therapies Virus Hospitals 52

The Pharma Data

OCTOBER 22, 2020

Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. kg or hospitalized pediatric patients weighing 3.5

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

OCTOBER 27, 2021

. “The main finding in our study is that the equine hyperimmune globulins antibodies developed against the spike protein of the ancestral SARS-CoV-2 had high neutralizing action against the new variants of the virus, such as the gamma strain.

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

APRIL 3, 2021

The study aimed to determine whether an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine (referred to by the Alliance as CoVIg-19) could reduce the risk of disease progression when added to standard of care treatment including remdesivir in hospitalized adult patients at risk for serious complications.

Clinical Trials 52

Clinical Trials Trials Treatment Hospitals 52

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. HCV Research. COVID-19 Research.

Virus 40

Virus Treatment Science Trials 40

The Pharma Data

DECEMBER 14, 2020

Specifically, it is being examined in adults who are hospitalized with COVID-19. The collaboration was meant to leverage Kiadis’ K-NK cell therapy platform. Under the collaboration agreement, researchers are looking into the elimination of the SARS-CoV-2 virus and virally infected cells by K-NK cells.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

SEPTEMBER 5, 2021

. “This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

OCTOBER 19, 2020

. “Innovation in cancer treatment is realized through collaboration, and the physicians and researchers at Emory’s Winship Cancer Institute have consistently shown their commitment to developing novel cancer therapies using this collaborative approach,” said Chadi Nabhan , M.D., Ramalingam , M.D.,

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

JUNE 1, 2022

With more than two decades of biopharmaceutical R&D experience, Dr. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. 6-8 Patients with severe asthma account for twice as many asthma-related hospitalizations. 2018 for patients with severe asthma, without an eosinophilic phenotype. Tezepelumab was very well tolerated in patients with severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

Codon

JUNE 11, 2024

Hospitals harness this speed to sequence and analyze tumor DNA within 6 hours , more than twice as fast as similar analyses performed using traditional next-generation sequencing , such as Illumina. Stephen Malina is Head of Engineering at Dyno Therapeutics, a company using machine learning to design better viral vectors for gene therapy.

DNA 87

DNA Engineering RNA Small Molecule 87

The Pharma Data

NOVEMBER 4, 2020

With years of extensive experience in the field of skin health, the Company has successively built the “Juyou” brand for skin barrier repair, now recommended by thousands of public hospitals in China ; the professional baby skincare brand “Juyou Baby”, as well as the “Dermacid” brand, just to name a few.

Licensing 40

Licensing Licensing Production Engineering 40

The Pharma Data

OCTOBER 29, 2020

. “Our foundation for the future is stronger than ever, and by maintaining our focus on serving patients and delivering for shareholders, I am confident that we will continue to build on our success to date and further advance our mission of delivering life-changing therapies to people with rare diseases and devastating conditions.”

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 131

Therapies Virus DNA Clinical Trials 131

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D.,

Government 52

Government Hospitals Virus Clinical Trials 52

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

JANUARY 13, 2021

patients hospitalized with COVID-19. Patient Population: 45 hospitalized patients with COVID-19. Primary Endpoint: Proportion of patients recovered from COVID-19 and no longer hospitalized at Day 29. LONDON and RALEIGH, N.C., David Zaccardelli, Pharm. About Verona Pharma.

Hospitals 52

Hospitals Clinical Trials Therapies Treatment 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Broad Institute

DECEMBER 6, 2023

In the future, when doctors give patients cytokine therapies targeting the immune system, they could potentially look in the Immune Dictionary for expected cell-level immune responses. By Allessandra DiCorato December 6, 2023 Credit: Len Rubenstein (right photo) Ang Cui (left) and Nir Hacohen (right). What makes this study significant?

Immune Response 138

Immune Response RNA Disease Medical Schools 138

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. Oakville, Ontario–(Newsfile Corp. Dr. . Cardiol Therapeutics Inc. (

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. It works to block the “spike protein” in the virus before it can enter human cells and cause illness. TAMPA, Fla., News and World Report’s national university rankings than USF.

Hospitals 40

Hospitals Treatment Virus Nurses 40

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Bamlanivimab and etesevimab together and bamlanivimab alone are not authorized for use in patients: who are hospitalized due to COVID-19, OR. who require oxygen therapy due to COVID-19, OR. Limitations of Authorized Use.

Government 52

Government Hospitals Long-Term Care Facilities Treatment 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? There’s a TV show where a bunch of doctors are walking through a hospital corridor. approved a gene therapy for hemophilia A for the first time. The therapy works by replacing beta-cells with “fresh” cells taken from a, err…dead person.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? There’s a TV show where a bunch of doctors are walking through a hospital corridor. approved a gene therapy for hemophilia A for the first time. The therapy works by replacing beta-cells with “fresh” cells taken from a, err…dead person.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA).

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

JULY 29, 2021

Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The Cell Therapy product sales increased 39% to $219 million for the second quarter 2021 compared to the same period in 2020.

Science 52

Science Production Treatment FDA 52

The Pharma Data

SEPTEMBER 30, 2021

We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”.

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. This is the focus of vaccines in development and convalescent plasma therapy. The test targets antibodies against the spike protein. said Thomas Schinecker, CEO Roche Diagnostics.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

JULY 8, 2021

Tezepelumab was granted an FDA Breakthrough Therapy Designation for patients with severe asthma without an eosinophilic phenotype in September 2018. 2,6,9) Patients with severe uncontrolled asthma have twice the risk of asthma-related hospitalizations.(10,11) About Severe Asthma. Globally, there are approximately 2.5

FDA 52

FDA Trials Therapies Treatment 52